Response to Office communication dated: 11/22/2006

Attorney Docket: UCONAP/141/US

Please amend the claims as follows:

1-22. cancelled

23. (previously presented) The method of claim 28 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof

$$AA - C - NH - C_2H_5, \quad AA - C - NH \rightarrow OH \quad AA - C - O - C_4H_2OH$$

$$AA - C - O - C \rightarrow OH \quad AA - C - N \rightarrow OH$$

$$AA - C - N \rightarrow OH \quad AA - C - N \rightarrow OH$$

$$AA - C - N$$

Response to Office communication dated: 11/22/2006

Attorney Docket: UCONAP/141/US

24. (previously presented) The method of claim 28 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

$$AA - C - NH - C_2H_5, \quad AA - C - NH \qquad OH \qquad AA - C - O - C_4H_2OH \qquad OH \qquad AA - C - NH \qquad O$$

25. (previously presented) The method of claim 28 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

Response to Office communication dated: 11/22/2006

Attorney Docket: UCONAP/141/US

26. cancelled

27. (currently amended) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a pharmacological preparation comprising a therapeutically effective amount of a compound represented by the following structural formula and physiologically acceptable salts thereof:

Response to Office communication dated: 11/22/2006

Attorney Docket: UCONAP/141/US

28. (previously presented) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a <u>pharmacological preparation comprising a</u> compound represented by the following structural formula and physiologically acceptable salts thereof

AA
$$-C$$
 $-NH$ $-C_2H_5$ AA $-C$ $-NH_2$ AA $-C$ $-O$ $-C_4H_2OH$ AA $-C$ $-O$ $-C_4H_2OH$ AA $-C$ $-O$ $-$

Response to Office communication dated: 11/22/2006

Attorney Docket: UCONAP/141/US

29. (new) The method of claim 24 wherein the compound is in isolated and

substantially purified form.

30. (new) The method of claim 24 wherein the pharmacological preparation further

comprises at least one member selected from an excipient, a vehicle, an adjuvant, a

flavoring, a colorant, or a preservative and the compound is in isolated and substantially

purified form.

31. (new) The method of claim 27 wherein the compound is in isolated and

substantially purified form.

32. (new) The method of claim 27 wherein the pharmacological preparation further

comprises at least one member selected from an excipient, a vehicle, an adjuvant, a

flavoring, a colorant, or a preservative and the compound is in isolated and substantially

purified form.

33. (new) The method of claim 28 wherein the compound is in isolated and

substantially purified form.

34. (new) The method of claim 28 wherein the pharmacological preparation further

comprises at least one member selected from an excipient, a vehicle, an adjuvant, a

flavoring, a colorant, or a preservative and the compound is in isolated and substantially

purified form.

6